透析患者高草酸盐浓度与心源性猝死风险增加相关
该研究基于德国4D研究的事后分析,纳入1255例接受血液透析的欧洲糖尿病患者,中位随访4年。结果显示,血清草酸盐最高四分位组(≥59.7 µM)患者心血管事件风险增加40%(aHR 1.40),心源性猝死风险增加62%(aHR 1.62),并在104例美国透析患者队列中验证。
要点
- 透析患者血清草酸盐升高与心血管事件和心源性猝死风险独立相关。
- 最高四分位组(≥59.7 µM)心血管事件风险增加40%,心源性猝死风险增加62%。
- 草酸盐作为连续变量及竞争风险模型下关联仍稳健。
核心结论
- 血清草酸盐升高是透析患者心血管事件和心源性猝死的新风险因素。
- 需进一步研究降草酸盐策略能否改善透析患者心血管死亡率。
研究设计与样本
- 德国糖尿病透析(4D)研究的事后分析,纳入1255例接受血液透析的欧洲糖尿病患者,中位随访4年。
- 在104例美国透析患者队列中验证,中位随访2.5年。
主要发现
- 1108例患者有基线草酸盐测量,中位草酸盐浓度为42.4 µM。
- 随访期间548例死亡,其中139例(25.4%)死于心源性猝死。
- 413例达到主要复合心血管终点(心源性死亡、非致死性心肌梗死、致死或非致死性卒中)。
- 最高四分位组(≥59.7 µM)较低分位组(≤29.6 µM)心血管事件风险增加40%(aHR 1.40;95% CI 1.08–1.81)。
- 最高四分位组(≥59.7 µM)较低分位组(≤29.6 µM)心源性猝死风险增加62%(aHR 1.62;95% CI 1.03–2.56)。
临床怎么用
- 透析患者可关注血清草酸盐水平,高草酸盐或提示心血管事件和心源性猝死高风险。
- 目前尚无证据支持降草酸盐治疗改善预后,需等待进一步研究。
局限性
- 4D研究为事后分析,原始研究纳入的是糖尿病患者。
- 验证队列样本量较小(104例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical significance of accumulating toxic terminal metabolites such as oxalate in patients with kidney failure is not well understood. METHODS: To evaluate serum oxalate concentrations and risk of all-cause mortality and cardiovascular events in a cohort of patients with kidney failure requiring chronic dialysis, we performed a post-hoc analysis of the randomized German Diabetes Dialysis (4D) Study; this study included 1255 European patients on hemodialysis with diabetes followed-up for a median of 4 years. The results obtained via Cox proportional hazards models were confirmed by competing risk regression and restricted cubic spline modeling in the 4D Study cohort and validated in a separate cohort of 104 US patients on dialysis after a median follow-up of 2.5 years. RESULTS: A total of 1108 patients had baseline oxalate measurements, with a median oxalate concentration of 42.4 µM. During follow-up, 548 patients died, including 139 (25.4%) from sudden cardiac death. A total of 413 patients reached the primary composite cardiovascular end point (cardiac death, nonfatal myocardial infarction, and fatal or nonfatal stroke). Patients in the highest oxalate quartile (≥59.7 µM) had a 40% increased risk for cardiovascular events (adjusted hazard ratio [aHR], 1.40; 95% confidence interval [95% CI], 1.08 to 1.81) and a 62% increased risk of sudden cardiac death (aHR, 1.62; 95% CI, 1.03 to 2.56), compared with those in the lowest quartile (≤29.6 µM). The associations remained when accounting for competing risks and with oxalate as a continuous variable. CONCLUSIONS: Elevated serum oxalate is a novel risk factor for cardiovascular events and sudden cardiac death in patients on dialysis. Further studies are warranted to test whether oxalate-lowering strategies improve cardiovascular mortality in patients on dialysis.
引用
- Pfau A, Ermer T, Coca SG, et al. High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis Patients. J Am Soc Nephrol. 2021. PMID: 34281958. doi:10.1681/ASN.2020121793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。